Navigation Links
Significant Milestone Marks the Beginning of FDA-Authorized Breast Cancer Trial
Date:7/14/2009

TAMPA, Fla., July 14 /PRNewswire/ -- Quantum Immunologics, Inc. (QI), a Tampa, Florida company focusing on the research and development of cancer immunotherapies, announces that the first patient in its breast cancer trial has begun to receive its dendritic cell therapy.

QI is currently sponsoring and conducting an FDA-authorized Phase I/II clinical trial testing the safety and efficacy of its immunotherapy on 27 Stage IV breast cancer patients who have failed conventional therapy. According to Mr. Chuck Broes, CEO of QI, "This achievement marks a significant milestone in the life cycle of our company, and we look forward with great hope and commitment as we aspire to a successful trial outcome."

The clinical trials involve the use of dendritic cell therapy using the oncofetal antigen ("OFA"), or iLRP -- immature Laminin Receptor Protein, as a cancer antigen (a protein found on cancer cells that can be targeted by the body's own immune system) found in many tumor cell lines or fetal tissue, but absent on normal, healthy tissue. QI believes that the OFA antigen can serve as a unique, valuable and promising antigen for individualized breast cancer immunotherapy.

Centered in Mobile, AL, QI's clinical trial is designed around the use of QI's proprietary dendritic cell therapy, which employs OFA to recruit the patient's own immune system to target and attack the cancer cells with the intent to improve patient survivability and quality of life. Each patient will receive three monthly injections of the patient's own dendritic cells that have been sensitized to OFA. It is anticipated that once the sensitized cells are injected back into the patient, the patient's T-cells will locate the OFA found on the patient's cancer cells, thereby generating an immune response with the goal of killing the cancer cells and preventing further spread of the disease.

Abo
'/>"/>

SOURCE Quantum Immunologics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment
2. Spectral announces publication demonstrating Toraymyxin(TM) significantly reduces mortality from sepsis in prospective controlled trial
3. Buehler Motor, Inc., Significantly Expands Customer and Partner Support in North America
4. Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkins Lymphoma
5. PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer
6. PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
7. Immunotherapy-Based Provisional Patents Mark Significant Discovery
8. Cord Blood America Sees Significant Positives in President Obamas Lifting of Stem Cell Funding Restrictions
9. Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008
10. Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value
11. iCardiac Reports Significant Revenue Growth and Profitability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... , ... August 04, 2015 , ... On August 4, ... a diverse selection of entrepreneurs from across the United States to talk about their ... is honored to be chosen to be among the attendees. , One of the ...
(Date:8/3/2015)... DIEGO , Aug. 3, 2015  Halozyme Therapeutics, ... Update Conference Call for the second quarter 2015 on ... PT. Dr. Helen Torley , president and chief ... date post-market, Halozyme will release financial results for the ... webcast live through the "Investors" section of Halozyme,s corporate ...
(Date:8/3/2015)... Ga. , Aug. 3, 2015  MiMedx Group, ... company utilizing human amniotic tissue and patent-protected processes to ... Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and ... present at the 35 th Annual Canaccord|Genuity Growth ... H. "Pete" Petit, Chairman and CEO, William C. ...
(Date:8/3/2015)... ... ... Nine field days to promote practices that improve soil health will take ... Partnership , the field days will demonstrate how changing certain practices, such as adding ... , Brent Bible has practiced no-till farming and planted cover crops on his farm ...
Breaking Biology Technology:White House Invites uBiome CEO Jessica Richman to First-Ever Startup Demo Day 2Halozyme to Host Second Quarter 2015 Financial Results Conference Call 2MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2Soil Health Field Days Kick Off Throughout Midwest 2Soil Health Field Days Kick Off Throughout Midwest 3
... pleased to announce,that James Reddoch, Ph.D., has joined the ... has 17 years of experience in the,biotechnology sector. He ... analyst,most recently as Managing Director, Biotechnology and Group Head,Healthcare, ... of America,Securities, and CIBC World Markets Corp. (now Oppenheimer ...
... Pharmaceutical Institute, a,subsidiary of Campbell Alliance, the leading ... industry, today announced,the release of a revised edition ... environment and offering key new insights on how,pharmaceutical ... of "Understanding Pharma" analyzes nine key functional,areas within ...
... Knowledge Enterprises, Inc.,and The Institute for Orthopaedics ... Industry Annual Report, the premiere source for,objective, ... 200,page Annual Report summarizes the global orthopaedic ... Repair, Arthroscopy/Soft,Tissue Repair, Spinal Implants and Instrumentation, ...
Cached Biology Technology:Royalty Pharma Announces that James Reddoch, Ph.D., Joins Management Team 2Pharmaceutical Institute, in Collaboration With Campbell Alliance, Releases Second Edition of Breakthrough Book on the Inner Workings of the Pharmaceutical Industry 2Pharmaceutical Institute, in Collaboration With Campbell Alliance, Releases Second Edition of Breakthrough Book on the Inner Workings of the Pharmaceutical Industry 3Pharmaceutical Institute, in Collaboration With Campbell Alliance, Releases Second Edition of Breakthrough Book on the Inner Workings of the Pharmaceutical Industry 4Pharmaceutical Institute, in Collaboration With Campbell Alliance, Releases Second Edition of Breakthrough Book on the Inner Workings of the Pharmaceutical Industry 5Knowledge Enterprises, Inc. and The Institute for Orthopaedics(TM) Release The 2007-2008 Orthopaedic Industry Annual Report 2
(Date:7/31/2015)... La 10 th International Conference on Genomics ... 22 al 25 de octubre de 2015 en ... conferencia celebra su décimo aniversario. Desde su inauguración en el ... reuniones anuales más influyentes del mundo en el campo ,ómico, ... y mejores a nivel científico. ICG-10 se ...
(Date:7/31/2015)... , July 31, 2015 The 10 th ... held by BGI from October 22-25, 2015, in Shenzhen ... The conference is celebrating its 10 th anniversary this year. ... the world,s most influential annual meetings in the ,omics, fields, ... scientific gatherings. ICG-10 focuses on recent breakthroughs ...
(Date:7/27/2015)... July 27, 2015   Zynx Health ™, ... clinical improvement solutions, today announced that its ... available on Android smartphones and tablets. With this ... organizations can use ZynxCarebook to securely exchange messages ... streamline care transitions to other care settings, and ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3The 10th International Conference on Genomics (ICG-10) to Open in October 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... to 50 times using a new approach based on ... Vienna, told Chemistry & Industry, the magazine of the ... infects bacteria, can boost the effectiveness of antibiotics gentamicin, ... ability to channel through bacterial cell membranes that boosts ...
... by Johns Hopkins suggests that the rate of HIV-associated ... dementia along with Alzheimer’s disease and dementia from strokes ... in the world. , In the first study of ... and neuropsychological tests, 31 percent of a small but ...
... the May/June 2007 issue of the journal Ground Water, ... ground water due to incomplete human metabolism and excretion ... medications in the toilet or down the sink. ... in areas receiving waste water from septic tanks located ...
Cached Biology News:HIV dementia alarmingly high in Africa 2
... Orange G Dye runs faster ... in standard agarose gels.,Orange G dye ... nucleotides long. The migration at this ... bands, and,conveniently indicates the front of ...
... Anti-YAP Polyclonal Antibody ... rabbit polyclonal antibody. Detects 70 kDa ... Western blotting and immunohistochemistry. ... Storage: -20C ...
Rabbit polyclonal to QKI...
Mouse polyclonal antibody to QPRT - quinolinate phosphoribosyltransferase (nicotinate-nucleotide pyrophosphorylase (carboxylating))...
Biology Products: